How long did you take the drug before you got the desired result?

Here is the some steps to help you to save money on QUIXiN 0.5 % Ophthalmic Solution purchase.


Read drug prescription


What is QUIXiN 0.5 % Ophthalmic Solution

QUIXiN 0.5 % Ophthalmic Solution is in a group of antibiotics called fluoroquinolones. QUIXiN 0.5 % Ophthalmic Solution fights bacteria in the body.
QUIXiN 0.5 % Ophthalmic Solution is used to treat bacterial infections of the skin, sinuses, kidneys, bladder, or prostate. QUIXiN 0.5 % Ophthalmic Solution is also used to treat bacterial infections that cause bronchitis or pneumonia, and to treat people who have been exposed to anthrax or plague.
QUIXiN 0.5 % Ophthalmic Solution may also be used for purposes not listed in QUIXiN 0.5 % Ophthalmic Solution guide.

QUIXiN 0.5 % Ophthalmic Solution side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives, or the first sign of a skin rash; rapid heart rate, difficult breathing; swelling of your face, lips, tongue, or throat.
QUIXiN 0.5 % Ophthalmic Solution may cause swelling or tearing of (rupture) a tendon. QUIXiN 0.5 % Ophthalmic Solution can also have serious effects on your nerves, and may cause permanent nerve damage. Stop taking this medicine and call your doctor at once if you have:

Stop using QUIXiN 0.5 % Ophthalmic Solution and call your doctor at once if you have:

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
See also: Side effects (in more detail)

QUIXiN 0.5 % Ophthalmic Solution dosing

Usual Adult Dose for Nosocomial Pneumonia:

750 mg orally or IV every 24 hours for 7 to 14 days
Initial empiric treatment with broad-spectrum coverage according to the hospital's and/or ICU's antibiogram is recommended if multidrug-resistant organisms are suspected.
Duration: If the causative organism is not Pseudomonas aeruginosa, the duration of treatment should be as short as clinically possible to reduce the risk of superinfections with resistant organisms.

Usual Adult Dose for Pneumonia:

Community-acquired pneumonia:
Due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug resistant S pneumoniae [MDRSP]), Haemophilus influenzae, H parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae: 500 mg orally or IV every 24 hours for 7 to 14 days
Due to S pneumoniae (excluding MDRSP), H influenzae, H parainfluenzae, M pneumoniae, or C pneumoniae: 750 mg orally or IV every 24 hours for 5 days

Usual Adult Dose for Sinusitis:

Acute bacterial sinusitis: 500 mg orally or IV every 24 hours for 10 to 14 days or 750 mg orally or IV every 24 hours for 5 days

Usual Adult Dose for Bronchitis:

Acute bacterial exacerbation of chronic bronchitis: 500 mg orally or IV once a day for 7 days

Usual Adult Dose for Skin or Soft Tissue Infection:

Uncomplicated: 500 mg orally or IV once a day for 7 to 10 days
Complicated: 750 mg orally or IV once a day for 7 to 14 days

Usual Adult Dose for Prostatitis:

Chronic bacterial prostatitis: 500 mg orally or IV every 24 hours for 28 days

Usual Adult Dose for Urinary Tract Infection:

Complicated:
Due to Enterococcus faecalis, Enterobacter cloacae, E coli, K pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa: 250 mg orally or IV once a day for 10 days
Due to E coli, K pneumoniae, or P mirabilis: 750 mg orally or IV once a day for 5 days
Uncomplicated: 250 mg orally or IV once a day for 3 days

Usual Adult Dose for Pyelonephritis:

Acute:
Due to Escherichia coli: 250 mg orally or IV once a day for 10 days
Due to E coli : 750 mg orally or IV once a day for 5 days

Usual Adult Dose for Cystitis:

250 mg orally or IV once a day for 3 days

Usual Adult Dose for Anthrax Prophylaxis:

Prophylaxis postexposure to inhalational Bacillus anthracis: 500 mg orally or IV once a day for 60 days after exposure

Usual Adult Dose for Plague:

For treatment of plague and prophylaxis for plague: 500 mg orally or IV once a day for 10 to 14 days
Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis. Higher doses (750 mg orally or IV once a day) can be used for treatment of plague if clinically indicated.

Usual Adult Dose for Plague Prophylaxis:

For treatment of plague (including pneumonic and septicemic plague) and prophylaxis for plague: 500 mg orally or IV once a day for 10 to 14 days
Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis. Higher doses (750 mg orally or IV once a day) can be used for treatment of plague if clinically indicated.

Usual Adult Dose for Inhalation Bacillus anthracis:

Mass casualty treatment: 500 mg orally or IV once a day for 60 days
The Working Group on Civilian Biodefense has suggested that, based on in vitro studies, QUIXiN 0.5 % Ophthalmic Solution could be used for treatment of inhalational anthrax if ciprofloxacin and doxycycline are not available. One or two additional antibiotics with activity against the causative organism (e.g., rifampin, vancomycin, penicillin, ampicillin, chloramphenicol, imipenem, clindamycin, or clarithromycin) should be added.

Usual Adult Dose for Tuberculosis -- Active:

(Not approved by FDA)
500 to 1000 mg orally or IV once a day
This regimen has been recommended by the Centers for Disease Control and Prevention (CDC), the Infectious Diseases Society of America, and American Thoracic Society.
May be given in combination with at least 3 other active drugs for treatment of multi-drug resistant TB, or when the patient is intolerant of first-line agents. AFB smear and culture should be monitored monthly.
Duration: Treatment for TB should generally continue for 18 to 24 months, or for 12 to 18 months after culture results are negative.

Usual Adult Dose for Nongonococcal Urethritis:

CDC recommendations: 500 mg orally once a day for 7 days
QUIXiN 0.5 % Ophthalmic Solution therapy is recommended as an alternative regimen. Single-dose azithromycin is a preferred regimen.
The patient's sexual partner(s) should also be evaluated/treated.

Usual Adult Dose for Chlamydia Infection:

(Not approved by FDA)
CDC recommendations: 500 mg orally once a day for 7 days
QUIXiN 0.5 % Ophthalmic Solution therapy is recommended as an alternative regimen. Single-dose azithromycin is a preferred regimen.
The patient's sexual partner(s) should also be evaluated/treated.

Usual Adult Dose for Pelvic Inflammatory Disease:

CDC recommendations:
Mild to moderately severe acute PID: 500 mg orally once a day for 14 days
Due to high rates of resistance, the CDC does not recommend fluoroquinolones for treatment of gonococcal infections in the United States. As a result, regimens that include a quinolone are not recommended for the treatment of PID. If parenteral cephalosporin therapy is not possible, oral QUIXiN 0.5 % Ophthalmic Solution (with or without oral metronidazole) can be considered if community prevalence and individual risk for gonorrhea are low. Prior to therapy, diagnostic tests for gonorrhea must be performed. If test results are positive for quinolone-resistant Neisseria gonorrhoeae and cephalosporin therapy is not possible, single-dose azithromycin should be added to this quinolone-based PID regimen.
If patients do not respond to oral therapy within 72 hours, they should be reevaluated and parenteral therapy should be initiated.

Usual Adult Dose for Epididymitis -- Sexually Transmitted:

(Not approved by FDA)
CDC recommendations: 500 mg orally once a day for 10 days
The patient's sexual partner(s) should also be evaluated/treated.
All patients should receive ceftriaxone plus doxycycline for initial (empiric) treatment. Additional therapy can include QUIXiN 0.5 % Ophthalmic Solution if testing determines acute epididymitis is not caused by gonorrhea or if the infection is most likely caused by enteric organisms.
Due to high rates of resistance, the CDC does not recommend fluoroquinolones for treatment of gonococcal infections in the United States. Ceftriaxone is the first-line agent recommended for the treatment of gonococcal infections in the United States. Antimicrobial susceptibility patterns should be monitored.

Usual Pediatric Dose for Anthrax Prophylaxis:

Prophylaxis postexposure to inhalational B anthracis:
6 months or older:
Less than 50 kg: 8 mg/kg orally or IV every 12 hours for 60 days; not to exceed 250 mg per dose
50 kg or more: 500 mg orally or IV every 24 hours for 60 days

Usual Pediatric Dose for Plague:

For treatment of plague and prophylaxis for plague:
6 months or older:
Less than 50 kg: 8 mg/kg orally or IV every 12 hours for 10 to 14 days; not to exceed 250 mg per dose
50 kg or more: 500 mg orally or IV every 24 hours for 10 to 14 days
Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis.

Usual Pediatric Dose for Plague Prophylaxis:

For treatment of plague (including pneumonic and septicemic plague) and prophylaxis for plague:
6 months or older:
Less than 50 kg: 8 mg/kg orally or IV every 12 hours for 10 to 14 days; not to exceed 250 mg per dose
50 kg or more: 500 mg orally or IV every 24 hours for 10 to 14 days
Drug administration should begin as soon as possible after suspected or confirmed exposure to Yersinia pestis.

Select the most affordable brand or generic drug


StrengthQuantityPrice, USDCountry
Alevo 250mg Tablet $0.06Alkem Laboratories Ltd
Alevo 500mg Tablet $0.09Alkem Laboratories Ltd
750 mg x 10's $1.34
Flevoxcin 500 mg x 10's $1.46
Flevoxcin tab 500 mg 10's $1.46GXI
Levoact 750mg TAB / 10 $1.47
Levoact 500mg TAB / 10 $1.12
750 mg x 10's $1.54
Levodak 750mg TAB / 10 $1.54
LEVODAK tab 750 mg x 10's $1.90Zodak
500 mg x 10's $1.15
Levodak 500mg TAB / 10 $1.15
LEVODAK tab 500 mg x 10's $1.32Zodak
Nirliv 500mg Tablet $0.00Nirlife Healthcare
Nirliv NA Infusion $0.00Nirlife Healthcare
NIRLIV 500MG TABLET 1 strip(s) (10 tablets each) $0.02Nirlife Healthcare
NIRLIV INFUSION 1 bottle(s) (100 ML infusion each) $0.39Nirlife Healthcare
NIRLIV infusion 500 mg x 100ml $1.33Nirma (Nirlife)
Nirliv 500mg INF / 100ml $1.33
QULEF film-coated tab 250 mg x 5's $0.27Hetero HC (Kris)
QULEF film-coated tab 500 mg x 5's $0.53Hetero HC (Kris)
Qulef 750mg FILCOTAB / 5 $0.67

References

  1. Dailymed."Levofloxacin: dailymed provides trustworthy information about marketed drugs in the united states. dailymed is the official provider of fda label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. "Levofloxacin". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
  3. "Levofloxacin". http://www.drugbank.ca/drugs/DB0113... (accessed August 28, 2018).

QUIXiN 0.5 % Ophthalmic Solution - Frequently asked Questions

Can QUIXiN 0.5 % Ophthalmic Solution be stopped immediately or do I have to stop the consumption gradually to ween off?

In some cases, it always advisable to stop the intake of some medicines gradually because of the rebound effect of the medicine.

It's wise to get in touch with your doctor as a professional advice is needed in this case regarding your health, medications and further recommendation to give you a stable health condition.

Who should not take QUIXiN 0.5 % Ophthalmic Solution?

You should not use this medication if you are allergic to QUIXiN 0.5 % Ophthalmic Solution or other fluoroquinolones.

You may not be able to use QUIXiN 0.5 % Ophthalmic Solution if you have a muscle disorder. Tell your doctor if you have a history of myasthenia gravis.

To make sure QUIXiN 0.5 % Ophthalmic Solution is safe for you, tell your doctor if you have:

QUIXiN 0.5 % Ophthalmic Solution may cause swelling or tearing of a tendon (the fiber that connects bones to muscles in the body), especially in the Achilles' tendon of the heel. This can happen during treatment or up to several months after you stop taking QUIXiN 0.5 % Ophthalmic Solution. Tendon problems may be more likely to occur if you are over 60, if you take steroid medication, or if you have had a kidney, heart, or lung transplant.

FDA pregnancy category C. It is not known whether QUIXiN 0.5 % Ophthalmic Solution will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication.

It is not known whether QUIXiN 0.5 % Ophthalmic Solution passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine.

How should I take QUIXiN 0.5 % Ophthalmic Solution?

Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended.

Take QUIXiN 0.5 % Ophthalmic Solution at the same time each day with a full glass of water (8 ounces). Drink several extra glasses of fluid each day while you are taking QUIXiN 0.5 % Ophthalmic Solution. You may take QUIXiN 0.5 % Ophthalmic Solution tablets with or without food.

Take QUIXiN 0.5 % Ophthalmic Solution oral solution (liquid) on an empty stomach 1 hour before or 2 hours after meals. Measure liquid medicine with a special dose-measuring spoon or medicine cup. If you do not have a dose-measuring device, ask your pharmacist for one.

Use this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. QUIXiN 0.5 % Ophthalmic Solution will not treat a viral infection such as the common cold or flu.

This medication can cause you to have a false positive drug screening test. If you provide a urine sample for drug screening, tell the laboratory staff that you are taking QUIXiN 0.5 % Ophthalmic Solution.

Do not share this medication with another person (especially a child), even if they have the same symptoms you have.

Store at room temperature away from moisture and heat. Keep the bottle tightly closed when not in use.

What other drugs will affect QUIXiN 0.5 % Ophthalmic Solution?

Tell your doctor about all medicines you use, and those you start or stop using during your treatment with QUIXiN 0.5 % Ophthalmic Solution, especially:

This list is not complete. Other drugs may interact with QUIXiN 0.5 % Ophthalmic Solution, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.

Can QUIXiN 0.5 % Ophthalmic Solution be taken or consumed while pregnant?

Please visit your doctor for a recommendation as such case requires special attention.

Can QUIXiN 0.5 % Ophthalmic Solution be taken for nursing mothers or during breastfeeding?

Kindly explain your state and condition to your doctor and seek medical advice from an expert.

Reviews

Following the study conducted by gmedication.com on QUIXiN 0.5 % Ophthalmic Solution, the result is highlighted below. However, it must be clearly stated that the survey and result is based solely on the perception and impression of visitors and users of the website as well as consumers of QUIXiN 0.5 % Ophthalmic Solution. We, therefore, urge readers not to base their medical judgment strictly on the result of this study but on test/diagnosis duly conducted by a certified medical practitioners or physician.

Patient reports

Patient reported useful

No survey data has been collected yet


Patient reported side effects

No survey data has been collected yet


Patient reported price estimates

No survey data has been collected yet


Patient reported frequency of use

No survey data has been collected yet


Patient reported doses

No survey data has been collected yet


Patient reported time for results

No survey data has been collected yet


Patient reported administration

No survey data has been collected yet


Patient reported age

No survey data has been collected yet


Patient reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 1 here

The information was verified by Dr. Vishal Pawar, MD Pharmacology